ICU Medical, Incorporated (ICUI) 2017年年度报告「NASDAQ」.pdf

1、 2017 Annual Report to Shareholders and Form 10-KCritical CareI nnovative hemodynamic monitoring systems for patient fluid assessment,advanced sensor catheters,and pressure transducers.I V ConsumablesClinically proven needlefree I V connectors,gravity sets,closed system transfer devices(CSTDs),I V c

2、atheters,and disinfectant I V caps.I V SolutionsA complete line of I V solutions including sterile solutions,irrigation solutions,and certain nutritionals.I V SystemsI ndustry-leading large volume,ambulatory,and PCA pumps,dedicated I V sets,I V medication safety software,and field service.We are the

3、 only company focused exclusively on I V therapy across the continuum of careFor more than three decades,we have been dedicated to a singular purposeimproving the safety and efficiency of I V therapy.With the acquisition of Hospira I nfusion Systems from Pfizer in 2017,we became the only company to

4、focus exclusively on I V therapy across the continuum of care.We connect patients and caregivers through safe,life-saving,life-enhancing medical devicesApril 5,2018 Dear Stockholder:Fiscal 2017 was a unique year for ICU Medical following the close of our acquisition of the Hospira Infusion Systems(H

5、IS)business in February.It is unusual to see a company acquire another company almost four times its size,but the transaction solved our main historical strategic challenge of customer concentration and created a more sustainable company that can continue to build shareholder value.We are now a lead

6、ing pure-play infusion company with a full-line portfolio and unified distribution channels globally that give us the opportunity for continued performance improvement.We continue to believe that we structured a sensible transaction that did not take on too much risk,and we finished the year with ne